Global vaccines research
Following a global vaccination effort in response to the COVID-19 pandemic, momentum has gathered pace for developing vaccines across multiple therapy areas – the area is going beyond prevention and is also being explored for treatment of illnesses and conditions. Our research suggests that increasing levels of vaccine fatigue amongst the general population following the pandemic is now a key challenge that could be faced. Ipsos’ studies continue to track changing perceptions around vaccines and likelihood to receive or recommend them.
You can find our latest insights and opinions below.
News & polls | Articles & papers | Webinars, videos & podcasts | Services
News & polls
Data Dive: How the COVID-19 pandemic shaped views - Global polling insights about the coronavirus crisis’ impact on everything, including views on vaccines. October 2022
Covid-19: Expectations and vaccination - A survey for the World Economic Forum finds the majority of people believe we’ll never fully stop the spread of COVID, but views on vaccination mandates vary. February 2022
Articles & papers
RSV: The race to market continues – Several companies remain key contenders to launch the first respiratory syncytial virus (RSV) vaccine
RSV: On the verge of change – After decades of failed attempts, the respiratory syncytial virus (RSV) treatment and vaccine landscape is on the verge of profound change.
Expanding Flu Vaccine Access - Polling commissioned by AstraZeneca on Ipsos’ KnowledgePanel® found that broadening the availability of a nasal spray to those not already vaccinated could increase flu vaccine uptake for children and adults under the age of 50.
Awareness of HPV Among Parents - MSD commissioned Ipsos to run a survey to support speakers at the European Week Against Cancer, taking place from 25 – 31 May 2022. The findings demonstrate the need to further boost HPV awareness and knowledge, to lead to greater vaccine uptake and ultimately lower the prevalence of cancer-causing HPV
Infographic: COVID-19: Vaccines, therapeutics & treatment impact – Perspectives from Ipsos's syndicated COVID-19 study portfolio.
Responding to Covid-19 in Africa: Finding the balance - Ipsos conducted public opinion polls on behalf of the Partnership for Evidence-Based Response to COVID-19 (PERC) in 19 African Union Member States to understand the public’s knowledge, risk perception, attitudes, access to information, reactions, behaviours and practices related to COVID-19. This report distills key insights from PERC’s fourth survey conducted in September 2021.
Webinars, videos & podcasts
Understanding the drivers of infant immunisation – In this 6-part series, Ipsos shares what stood out for them from nearly three years of research surrounding barriers to infant immunisation in sub-Saharan Africa
KEYS – The year in review: Making sense of 2021 - 2021 started with a mood of guarded optimism and at least some hope that the storm which came with Covid-19 could now be weathered. As the year drew to a close, Ipsos reflected on how people were feeling about this 12-month period and any lessons learned to take forward.
Click here to learn more about Ipsos’ global vaccines research capabilities, and how we can help answer your key questions:
Ipsos’ Global Syndicated Vaccine Study - Healthcare professionals, paediatricians, pharmacists and consumers
Ipsos’ Global Syndicated RSV Study – An extension of the Syndicated Vaccine Study covering attitudes and perceptions around RSV vaccination & immunisation
Playing the long game: will the ongoing evolution of the psoriasis market play out in atopic dermatitis?
With several advanced therapy options now available to treat moderate-severe atopic dermatitis - and more on the horizon - how is the treatment landscape changing? Can we use evolutions in psoriasis treatment as a proxy, and can we draw any parallels between physicians’ therapeutic goals?